BMO Capital Reiterates Outperform Rating, $325 Price Target on Vertex (VRTX) Following VX-880 Hold Lift

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $325.00 price target on Vertex (NASDAQ: VRTX).

The analyst comments: "FDA lifted the clinical hold on Vertex's Phase 1/2 trial of VX-880, a stem cell-derived islet cell replacement therapy for T1D, allowing the company to screen, enroll and dose in the US. Recall, Vertex achieved proof-of-concept in May, but the clinical hold concurrent with dosing a third patient with the target dose was unexpected. This update puts the program back on track to enroll patients in Part B and C in the US trial imminently."

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $287.32 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• Vertex Pharma (VRTX) Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
• Boston Beer Company (SAM) PT Lowered to $310 at Evercore ISI
• Rentokil Initial (RTO) PT Lowered to $35 at Oppenheimer